FDA-Cleared AI Software Targets Streak Artifacts in Cone-Beam CT
The CleaRecon DL software reportedly removes streak artifacts that can occur with the use of cone-beam computed tomography (CBCT) during interventional radiology procedures.
For interventional radiologists, GE HealthCare has unveiled CleaRecon DL, a deep learning software that addresses the challenge of streak artifacts that can hamper cone-beam computed tomography (CBCT) acquisitions during interventional procedures.
Recently cleared by the Food and Drug Administration (FDA), CleaRecon DL removes streak artifacts from CBCT reconstructed images, according to GE HealthCare.
Designed to remove streak artifacts from reconstructed cone-beam CT images, the FDA-cleared CleaRecon DL software reportedly bolsters image quality for interventional radiology procedures involving the prostate, liver, endovascular aortic repair, and neuroradiology applications, according to GE HealthCare, the manufacturer of the software. (Image courtesy of GE HealthCare.)
Employing deep learning algorithms, the company said CleaRecon DL facilitates improved image clarity during interventional radiology procedures involving the liver and prostate as well as neuroradiology applications and procedures involving endovascular aortic repair.
“The introduction of CleaRecon DL represents a leap forward in the interventional suite and for the advancement of CBCT. By improving image quality and reducing artifacts, this technology can empower clinicians to perform procedures with greater precision and confidence,” said Arnaud Marie, General Manager, Interventional Solutions at GE HealthCare.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
